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Summary.-We have studied the radiomodifying action in mouse skin of WR-2721
and misonidazole (MISO) when used alone or in combination. The radioprotection
with WR-2721 was drug-dose dependent and highly influenced bythe 02 concentration
at the time of irradiation. Significant sensitization was observed with MISO,
especially in air-breathing mice. The combination of WR-2721 and MISO produced
a radiation response intermediate between the resistant and sensitive responses to
either drug alone. The precise degree of sensitivity was dependent on the relative
doses of protector and sensitizer. We have also studied the interaction of both drugs
in terms of drug-induced lethality, which showed a clear toxic interaction. The
WR-2721 LD50 was reduced by a factor of 1-4 with only 200 mg/kg of MISO. We
conclude that the combination of WR-2721 and MISO shows an interaction in terms
of drug toxicity and radiation response, such that the radioprotection of skin is
reduced or even abolished with low doses of MISO.
CHEMICAL MODIFICATION ofthe response
ofcells to radiation has led to experimental
and clinical interest in radiosensitizers for
increasing tumour damage (Begg et al.,
1974; Urtasun et al., 1974; Denekamp &
Harris, 1975; Fowler & Denekamp, 1979;
Dische et al., 1979; Wasserman et al., 1981)
and in radioprotectors for reducing
normal-tissue injury (Phillips et al., 1973;
Tanaka & Sugahara, 1980; Kligerman et
al., 1980; Yuhas, 1981). Radiosensitizers
are believed to be tumour specific because
they are only effective on hypoxic cells
(Adams, 1978) and the radioprotectors
to be normal-tissue specific because
they selectively protect oxic cells (Harris
& Phillips, 1971) and may be preferen-
tially concentrated in normal tissues
(Yuhas & Storer, 1969; Yuhas, 1980).
The possibility of combining the inde-
pendent actions ofthese 2 groups ofdrugs
in radiation therapy is attractive, especi-
ally since only low doses of both pro-
tectors and sensitizers can be used be-
cause of their systemic toxicity. Yuhas
et al. (1977) and Sodicoff et al. (1979)
indicated that the combination of WR-
2721 with MISO in experimental radio-
therapy was advantageous, since in their
animal studies there was no additive
drug toxicity, and neither compound
interfered with the radiation-modifying
effect of the other. MISO did not decrease
the radioprotection of normal tissues and
WR-2721 did not diminish tumour radio-
sensitization, thus increasing the thera-
peutic gain.
These results seem somewhat surprising
in view of the many radiation chemistry
and in vitro experiments using combina-
tions of sensitizers and protectors. The
published experimental results can be
interpreted as a competition between
these compounds for radical lesions, result-
ing in either fixation or repair ofradiation-
induced damage to biological targets (e.g
Dewey, 1963; Willson & Emmerson, 1970;
Chapman et al., 1973; Kock & Howell,
1980, 1981).
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ments, similar to those of Yuhas and his
colleagues, in which the radioprotective
effect ofWR-2721 and the radiosensitizing
action of MISO used alone and in com-
bination, have been studied in both
tumours and normal tissues. This paper
reports the influence ofMISO or additional
02 on the radioprotection observed in
mouse skin with WR-2721. The tumour
results will be presented elsewhere (Rojas
et al., 1982).
MATERIALS AND METHODS
Specific-pathogen-free female almino mice
of the strain WHT (designated WHT/Gyf
BSVS) aged 2-3 months, were used for all
the experiments. The animals were caged in
groups of 5 and given free access to food and
water.
X-rays at 240 kV were generated in a
Pantak X-ray set, filtered with 0-25 mm Cu
and I 0 mm Al, to give a HVL of 1P3 mm
Cu, and a dose rate of2-2 Gy/min. Forirradia-
tion, unanaesthetized mice were loaded into
individual lead boxes with their left hind
limb gently immobilized in the beam (for
details see Douglas & Fowler, 1976).
Irradiations were performed at room
temperature (23 + 2°C) with mice surrounded
by air or 02- For the latter, the irradiation
jig was placed inside a polythene bag,
through which 100% 02 flowed at a rate of
6 1/min. Each dose group contained 5 mice.
WR-2721 (S-2-(3-aminopropylamino)ethyl
phosphorothioic acid, kindly provided by the
Developmental Program, Div. of Cancer
Treatment, NCI, Bethesda, U.S.A.) was
dissolved in saline for the first 2 experiments,
and subsequently in distilled water. The
WR-2721 doses used, whether alone or in
combination with MISO, represented 20-50%
of the LD50. The drug was given i.p. 30-40
min before irradiation. This has been shown
to be an adequate interval for obtaining
significant radioprotection in mouse skin
(Stewart & Rojas, 1982; Travis et al., 1982).
MISO (1-(2-nitroimidazole-1-yl)-3 methoxy-
propan-2-ol) kindly supplied by Roche Pro-
ducts Ltd., Welwyn Garden City) was
dissolved in saline and given i.p. 15 min
before WR-2721.
Skin reactions were scored 3 times a week
from 8 until 35 days after irradiation, using
an arbitary scale for erythema, desquamation
46
andulceration, as previouslydescribed (Dene-
kamp, 1973). The average skin reaction was
calculated for each group of mice over the
period 10-32 days, or an equivalent period
if the reaction appeared slightly earlier or
later.
RESULTS
Fig. 1 shows the toxic interaction
between WR-2721 and MISO in terms of
drug-induced lethality. The data have
been expressed as the percentage of
animals that died within 30 days when
graded doses of WR-2721 were given
alone or combined with fixed doses of
MISO. The LD50 for WR-2721 (1025
mg/kg) was reduced by a factor of 1-4
and 1-6 respectively, when 200 or 670
mg/kg of MISO was injected 15 min
before the radioprotector. Death in the
animals which received WR-2721 alone
occurred within 4 days. All animals
that died after receiving the drug com-
bination died within 24 h, as they would
from MISO alone, suggesting that the
radioprotectorenhancedtheMISO toxicity
rather than vice versa. The curves are
very steep, and the maximum tolerated
dose, in all 3 groups, is near the LD50.
However, we have found that under the
loor
LI)
0
0
w
0
z w
w
0L
7 0 000
(750) 1025)
a0
0 250 500 750 1000 1250
DOSE OF WR-2721 (mg/kg)
FIG. 1. Lethal toxicity of WR-2721 when
given alone (0) or in combination with
MISO (200 mg/kg, A; 670 mg/kg, 0).
The LD50 values obtained by profit fit to
the data are indicated. WR-2721 was more
toxic when combined with MISO.
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FIG. 2.-Dose-response curves (average
skin reaction over 10-32 days as a function
of X-ray dose) for mice irradiated in air
(triangles) or 02 (circles), with (- -) or
without ( ) 500 mg/kg WR-2721.
Each point represents the mean of 5 mice +
s.e. Animals irradiated in 02 were more
sensitive than those in air. WR-2721 pro-
tected the skin under both gas conditions.
experimental conditions used for irradia-
tions, the toxicity of WR-2721 alone, or
combined with MISO, increased markedly.
We therefore used doses well below the
maximum tolerated doses shown in Fig. 1.
Fig. 2 shows the results of an experi-
ment in which mice were irradiated in
air or 100% 02, with or without 500 mg/kg
WR-2721. Curves are drawn through each
set of data for the average skin reaction
over 10 to 32 days as a function of X-ray
dose. Three distinct responses were ob-
served. The most radiosensitive animals
were those treated in 02 without WR-
2721. The most radioresistant were those
treated in air with the protector. An
intermediate response was seen for mice
treated in air without drug, or in 02 with
the radioprotector. It is interesting that
reducing the 02 content of the ambient
gas from 100% to 21% gave the same
radioprotection as the administration of
500 mg/kg WR-2721 to mice breathing
100% 02. The protection achieved with
WR-2721 in air-breathing mice was greater
than that in 02 (Protection factor (PF) =
X-ray dose with WR-2721/X-ray dose
alone for equal damage) particularly at
low X-ray doses. This is consistent over all
our experiments (Table I) and suggests
competition between excess 02 and the
sulphydryl compound. Experiments using
MISO and WR-2721 have therefore been
in both 100% 02 and in air.
Fig. 3 shows the results from 3
experiments performed in 100% 02, with
various doses of WR-2721 and MISO.
Hardly any sensitization or protection
was observed with 200 mg/kg of either
drug alone, but with the higher doses
significant protection was observed with
WR-2721, and significant sensitization
with MISO. When MISO and WR-2721
were both present at the time ofirradiation
the degree of radioprotection or sensitiza-
tion was reduced. The dominant effect
(i.e. sensitization or protection) depended
upon the relative doses of the two drugs
in the combination.
The more extensive series of experi-
ments on air-breathing mice is sum-
marised in Fig. 4. The WR-2721 dose
increases from the top panels to the
bottom. With increasing WR-2721 dose
the degree of protection increases and is
consistently higher than in the experi-
ments performed in 02 (Fig. 3). Sensitisa-
tion by MISO was also considerably
greater in air than in the mice breathing
100% 02, and was quite marked with
500 mg/kg MISO. The response for
animals treated with both drugs was
always intermediate between full radio-
sensitization and full radioprotection, with
the predominant effect depending on the
relative drug doses. In the left-hand panels
(low MISO dose) protection predominates,
whereas in the right-hand panels (high
MISO dose) sensitization is more obvious.
From the data in Figs 2, 3 & 4 the
influence of the 3 radiation modifiers
(02, MISO and WR-2721) on skin radio-
sensitivity can be determined. Fig. 5
shows protection factors calculated from
the ratio of X-ray dose with WR-2721
(or with MISO) to the X-ray dose
alone to give the same skin reaction. The
vertical bars represent the range of PF
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FIG. 3.-Dose-response curves after irradiation in 02. Data are shown for mice treated with X-rays
alone or after administration ofMISO, WR-2721 or both. The drug doses (in mg/kg) were as follows
MISO: 670 in (a) and (b) 200 in (c). WR-2721: (a) 200 (b) 400 (c) 500. 670 mg/kg MISO sensitized
the skin, and 400-500 mg/kg WR-2721 protected it. The response in mice treated with both drugs
was intermediate, the sensitivity being dependent on the relative doses of MISO and WR-2721.
TABLE I.-Protectionfactorsfor skin after irradiation with WR-2721
(single dose)
Level of
skin damage
1.0
1-5
2 0
Gas
02
Air
02
Air
02
Air
200 mg/kg
1-07
1-28
1 -03
1-27
(0.97)*
1 -24
400 mg/kg
1-19
1-52
1-17
1 55
(1 - 17)*
1-5
500 mg/kg
1-20
1-64
1-09, 1-34t
1-62
1-3, 1-59t
1-43
* ( ) =values by extrapolation.
t =values from 2 separate experiments.
for skin-reaction levels of 1--2. Corres-
pondingly, for Fig. 6 the sensitizer en-
hancement ratio (SER) has been obtained
from the dose of X-rays alone to X-rays
plus MISO (or a combination), again for
skin reactions of 1-2. Fig. 5 shows that
the PF was lower in 02 than in air, but
in both situations there was a decrease in
skin radioprotection with increasing dose
of MISO. Similarly (Fig. 6) SER for
MISO was lower in 02 than in air, and
the addition of the WR-2721 could com-
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FIGc. 4.-Dose-response cutrves for mice irradiate(l in air. Data are shown for mice treated with
X-rays alone (x), with MISO (o and V7), with WR-2721 (0) or with both drugs (0). The drug
doses are indicated. The curve for mice treated with both (Irugs is intermediate between that for
MISO and for WR-2721, indicating a competition between sensitization and protection.
MISO (mg/kg)
0 200 500
1*18 0-92 0-882
1*45 1*15 0*95
1-54 1-21 1-06
* Average value from different experiments for
each drug dose.
pletely abolish it for certain drug com-
binations. In air the interaction effects
were more marked, with steeper slopes
for the curves of protection or sensitiza-
tion as a function of increasing MISO or
WR-2721 dose. These data indicate
competition between the radiation-modi-
fying actions of the sensitizer and the
protector (see Table II).
688
20[
1i-4
LV) D
C)4
m-
z
0
L.)
z
V)
LJ
LU
cx
iLL
1*
30
1.0
/ ~~~~/~20C
1-
I ay,,"4 /
/ | |
TABLE II. Protection factors* for
skin in air-breathing mice
WR-2721
(mg/kg)
200
400
500
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FIG. 5. WR-2721 protection factors for mice treated with varying doses of MISO. WR-2721 doses
(mg/kg): 200, ---; 400, - -; 500, . PF values for mice treated in air were obtained from
Fig. 4 and for mice treated in 02 from Fig. 3. The vertical bars represent the range of PF at skin-
reaction levels from 1 to 2. The WR-2721 PF decreases with increasing dose of MISO more
steeply in air than in 02.
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FIG. 6.-MISO sensitization for mice treated with WR-2721. MISO doses (mg/kg): - - -, 200;
5, 00 in air, 670 in 02. The SER values have been derived from the curves in Figs 3 & 4, at
reaction levels 1-2. MISO sensitization decreased with increasing WR-2721 dose, both in air and
in oxygen, demonstrating the interaction of these 2 drugs.
DISCUSSION
The experiments reported here show
that the radiosensitivity of mouse skin
can be easily modified, either in the
direction of greater sensitivity (by addi-
tional 02 or MISO) or in the direction of
greater resistance (by WR-2721). These
experiments were all performed on un-
anaesthetized mice. The data indicate
that mouse skin is not sufficiently oxy-
genated to be fully radiosensitive when
irradiated in air at 23 + 2°C. This result is
in accord with the observations of several
other authors (Fowler etal., 1965; Withers,
1967; Stewart et al., 1982). Although it is
known that the radiosensitivity of mouse
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skin is readily influenced by environ-
mental factors, including the surrounding
rather than the inspired gas (Potten &
Howard, 1969) a similar suboptimal oxy-
genation in air has been demonstrated
for several other normal tissues in rodents
(e.g. marrow, cartilage, intestine, oeso-
phagus and testis, see review by Hendry,
1979) clearly the clinical relevance of
these data depends upon whether the
mouse resembles man in its tissue 02
levels, and particularly on whether there
is a uniform low 02 tension which will
influence the response to low X-ray
doses, or a small proportion of severely
hypoxic cells which will only become
apparent at high X-ray doses (Hendry,
1979; Stewart et al., 1982).
Competitive interaction
The data presented in Figs. 2-6 and
in Table I indicate that significant radio-
protection of mouse skin was obtained
over the WR-2721 dose range used, in
both air and 02. The protection factors
varied with drug dose, but were also
strongly influenced by the 02 content of
the inspired gas. These data indicate a
competitive interaction between both
sensitizers (02 and MISO) and WR-2721.
This has previously been demonstrated
in vitro with various sulphydryl com-
pounds and electron-affinic radiosensi-
tizers, for mammalian cells, for bacteria
and for chemicals in solution (Dewey,
1963; Redpath & Willson, 1973; Chapman
et al., 1973; Asquith et al., 1974; Hall et
al., 1977; Cullen et al., 1980, Michael &
Harrop, 1980; Koch & Howell, 1980,
1981). The predominance of sensitization
or protection has been shown to depend
on the relative concentrations of the
compounds and on the 02 status. Pro-
tection by sulphydryls is generally much
greater in 02 than in hypoxic conditions
(see Alper, 1979, for review). Recently,
however, the dependence of radioprotec-
tion on the 02 concentration has been
shown to be more complex (Lunec et al.,
1981; Denekamp et al., 1981). The maxi-
mum radioprotection effect of dithioery-
thritol in vitro was obtained at 0.3%02,
with less protection in anoxia or in air
(Cullen et al., 1980). Similarly, using the
epidermal colony assay in vivo, the
maximum effect of WR 2721 was seen
in air, being reduced in 100% 02 or in low
02 concentrations (Denekamp et al.,
1981). Thus, both in vitro and in vivo the
maximum radioprotection was obtained
in the region of the "K" value* for 2,
i.e. in the region where small changes in
the available 02 have the most marked
effect on the radiosensitivity of the
system (Denekamp et al., 1981, 1982). The
early data of Dewey (1963) using very
high concentrations of cysteine and high-
pressure 02 on Serratia marcescens accord
with this conclusion.
Our data for MISO and WR 2721
also show a similar interaction. The
radiation-modifying action of either com-
pound could be reduced or eliminated by
an appropriate dose of the other (Fig.
5 & 6, Table II). These data are also
consistent with the hypothesis of redox
competition for radical fixation of the
initial chemical lesions that lead to
biological damage. They confirm in vivo
the basic mechanisms which have been
elucidated for competition between sensi-
tizers and protectors in the variety of
in vitro studies mentioned above.
Clinical application
Our data are more pessimistic in terms
of the potential clinical usefulness of the
drug combinations than earlier animal
studies (Yuhas et al., 1977; Sodicoff et al.,
1979; Grigsby & Maruyama, 1981). We
have been unable to confirm their state-
ments that there was independent action
of the 2 drugs, whether in terms of
toxicity, tumour sensitization or skin
protection.
The drug doses used in all these experi-
* The "K" value is the [02] at which half the maximum sensitization is obtained (Alper & Howard-
Flanders, 1956).
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ments are much higher than those likely
to be tolerated in man. At present, the
maximum tolerated dose clinically for
MISO is 12 gm/M2 in 6-30 fractions
(Dische et al., 1979) and for WR-2721
about 740 mg/M2 for a single dose (Blum-
berg et al., 1982). However, the interac-
tion that we have found between these
compounds occurs at all dose levels
tested, and presumably similar but cor-
respondingly smaller effects will pertain
at clinically relevant dose levels.
Fig. 1 shows a very clear increase in
WR-2721 toxicity if the animals are
treated 15 min earlier with 200 or 670
mg/kg MISO. This is in marked contrast
to the data of Yuhas et al. (1977) over the
same MISO dose-range, but agrees well
with the data of Grigsby & Maruyama
(1981).
Figs. 5 & 6 summarize our experiments
on the interaction of MISO and WR-2721
on the skin response to radiation. All 4
panels show a dose-dependent decrease in
protection or sensitization when the oppos-
ing agent is added. These data are similar
to the effect observed by Yuhas et al.
(1977) for marrow, and are more marked
than the slight interaction they reported
for skin reactions on tumour-bearing
limbs (Yuhas et al., 1977). We have
deliberately chosen to study normal-
tissue responses in areas not compromised
by a growing tumour, since the tumour
growth may influence the skin reaction
differentlv at different X-rays dose levels.
We have allowed a longer time for WR-
2721 penetration into the skin (30 min
vs. 15 min) because earlier studies indica-
ted that at least 30 min were needed to
obtain maximum radioprotection (Stewart
& Rojas, 1982; Travis et al., 1982). It
seems unlikely that this detail of timing
could account for the greater magnitude
of interaction in our studies, since the
protection factors with 400 mg/kg WR-
2721 alone are similar in our work and in
Yuhas's (1.36-1 55 vs. 145-1 66). Further-
more the concept of competitive inter-
action is supported by the 02 data since
a 5-fold increase in inspired 02 tension
for 1-2 min before irradiation can also
reduce the protection. Another report
on the combined action of MISO and
WR-2721 in normal tissues comes from
Sodicoff et al. (1979). They demon-
strated no reduction in the protection
factor for rat salivary glands in the
presence of 200 mg/kg MISO, but these ex-
periments used historical controls for
the rats treated with no drug or WR-2721
alone. Grigsby & Maruyama (1981) showed
interaction of WR-2721 and MISO on
the oral mucosa. They found a significant
reduction in WR-2721 radioprotection
with all the MISO combinations tested.
Thus the interaction of MISO and WR-
2721 has been demonstrated in 3 tissues
in vivo (skin, marrow and oral mucosa).
Yuhas et al. (1977) also reported the
effects of these 2 drugs separately and
in combination on a tumour. They saw
no interaction on the Line 1 carcinoma.
By contrast we have observed a marked
reduction in the MISO sensitization of
2 tumours (the fibrosarcoma SA FA
and the anaplastic tumour CA MT) when
the protector was added 30 min before
irradiation (i.e. 15 min after the sensi-
tizer). This interference with tumour
sensitization was seen, even when no
significant radioprotection by WR-2721
alone was obtained (Rojas et al. in pre-
paration). These data indicate to us that
competitive interaction can also occur in
tumours, and that the radioprotector can
diffuse and penetrate into the hypoxic
cells (Rojas et al., 1982). In both skin and
tumours the balance of the competition
between protection and sensitization de-
pends upon the relative doses of the 2
drugs.
These experiments show that the com-
bination of MISO and WR-2721 provides
a powerful tool for indirect investigation
of the 02 tension in the critical cells of
normal tissues. Previously, the lack of
correlation between radioprotection and
WR-2721 concentration in a tissue has
been inexplicable. Denekamp et al. (1982)
have proposed that small variations in
intracellular 02 tensions in different tissues
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may explain some ofthe wide variation in
the protection factors that have been
reported. For example, in the lung, which
shows high drug concentrations, the
high local 02 tensions may compete
effectively with the exogenous sul-
phydryls, reducing the overall protection.
Other tissues could show little protection
if their 02 tension were below the critical
range. The greatest protection would
then be expected in tissues with intra-
cellular 02 tensions critically close to the
oxygen "K" value. This hypothesis is
obviously open to experimental verifica-
tion by manipulation of the 02 content
in the inspired gas.
In summary, we are not optimistic
about the clinical potential of sensitizers
and protectors used in combination.
The additive toxicity, the reduced skin
radioprotection and the reduced tumour
sensitization indicate that a therapeutic
advantage is unlikely.
We wish to thank Professor J. F. Fowler for his
encouragement and constructive criticism of our
work and the Cancer Research Campaign for finan-
cial support.
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